| アブストラクト | In this study, we compared the similarities and differences in adverse events (AEs) among CAR T-cell products through signal mining via the FDA Adverse Event Reporting System (FAERS) and identified unknown AEs to provide a reference for safe clinical medication. Data from the FAERS database spanning from the fourth quarter of 2017 to the first quarter of 2024 were extracted. Signals were identified using the reporting odds ratio (ROR) method and the Medicines and Healthcare Products Regulatory Agency (MHRA) method. A total of 11,386 AE reports related to six CAR T-cell products were selected. The top three categories of AEs reported were nervous system disorders, immune system disorders, and general disorders and administration site conditions. However, there were variations in the AE spectra among the different CAR T-cell products. The BCMA-targeting drugs idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel) were found to be associated with parkinsonism, which were not observed in CD19-targeting drugs. Tisagenlecleucel (Tisa-cel) and axicabtagene ciloleucel (Axi-cel) exhibited cerebrovascular accident-related AEs, graft versus host disease, and abnormal coagulation indices. Cilta-cel was associated with cerebral hemorrhage, intracranial hemorrhage, cranial nerve disorder, and facial nerve disorder. Cardiopulmonary toxicity, including hypoxia, tachypnoea, cardiorenal syndrome, and hypotension, exhibited strong signal intensities and considerable overlap with CRS. The number of positive signals for cardiopulmonary toxicity associated with drugs targeting CD-19 is greater. Clinicians should assess patients prior to medication and closely monitor their vital signs, mental status, and laboratory parameters during treatment. |
|---|
| ジャーナル名 | Pharmaceuticals (Basel, Switzerland) |
|---|
| 投稿日 | 2024/8/31 |
|---|
| 投稿者 | Guo, Zihan; Ding, Yunlan; Wang, Mengmeng; Zhai, Qing; Liu, Jiyong; Du, Qiong |
|---|
| 組織名 | Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032,;China.;Department of Oncology, Shanghai Medical College, Fudan University, Shanghai;200032, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39204130/ |
|---|
